A narrative review published in Cardiology and Therapy examines the current scientific statements and consensus documents guiding cardiovascular evaluation for potential kidney transplant recipients. The study, authored by Jacob B. Michaud and colleagues, highlights a significant gap between established clinical guidelines and emerging evidence regarding the utility of routine asymptomatic cardiac screening. While cardiovascular disease remains the leading cause of mortality among individuals with kidney failure, the review suggests that the evidence supporting specific pre-transplant testing strategies remains sparse. The authors argue that substantial heterogeneity exists across transplant centers, with many institutions adhering to intensive screening protocols that may not yield clear short-term benefits for asymptomatic patients.
Cardiovascular disease affects up to 80% of patients undergoing hemodialysis, encompassing conditions such as heart failure, coronary heart disease, and arrhythmia. Despite this high prevalence, evidence-based strategies to lower cardiovascular risk in this population have historically been limited. Randomized trials and meta-analyses of single-agent risk-modifying therapies, including statins, beta-blockers, and renin-angiotensin system inhibitors, have not consistently demonstrated meaningful benefit in patients with advanced kidney failure. However, kidney transplantation itself has been repeatedly shown to increase survival, including cardiovascular-specific survival, compared to remaining on dialysis. This survival benefit holds true even among patients with documented coronary heart disease prior to transplantation.
The primary objective of the pre-transplant cardiovascular evaluation is to identify disease that requires optimized medical therapy or revascularization, as well as to detect conditions that may increase perioperative morbidity or impact graft longevity. Current guidelines from organizations such as the Kidney Disease: Improving Global Outcomes (KDIGO) and the American Heart Association (AHA) recommend noninvasive testing for high-risk, asymptomatic candidates. These recommendations are based on the need to balance the risks of surgery and immunosuppression against the benefits of transplantation. The review synthesizes these contemporary statements, noting that they generally advocate for more intensive preoperative cardiovascular evaluation than is recommended for other intermediate-risk elective procedures.
However, the diagnostic accuracy of noninvasive tests in patients with kidney failure is limited. Compared to invasive coronary angiography, single photon emission computed tomography myocardial perfusion studies have a sensitivity of only 53% to 66%, while coronary computed tomography angiography has a higher sensitivity but poor specificity of 63%. Dobutamine stress echocardiography sensitivity varies widely, ranging from 44% to 96% for significant coronary artery stenosis. These diagnostic limitations create uncertainty in clinical practice, as positive or negative test results may not reliably predict cardiovascular outcomes in the pre-transplant setting. The review highlights that data are inconsistent on whether these noninvasive tests accurately predict future cardiovascular events in potential kidney transplant recipients.
Management of detected coronary heart disease in the pre-transplant setting is further complicated by the lack of clear benefit from revascularization. The International Study of Comparative Health Effectiveness with Medical and Invasive Approaches–Chronic Kidney Disease (ISCHEMIA-CKD) trial showed no reduction in death or nonfatal myocardial infarction with routine revascularization over optimized medical therapy in patients with an estimated glomerular filtration rate of less than 30 ml/min/1.73 m². A post hoc analysis of this trial found that among listed kidney transplant candidates, the composite outcome did not differ between invasive and medical therapy strategies. These findings suggest that for most asymptomatic patients, optimized medical therapy may be as effective as invasive intervention, challenging the necessity of routine revascularization prior to transplantation.
The review also addresses the assessment of heart failure, arrhythmia, and valvulopathy, which account for a substantial proportion of cardiovascular mortality in kidney failure. Heart failure is associated with at least a twofold increase in mortality in patients with chronic kidney disease. Echocardiography is recommended for potential recipients, particularly those with symptoms or reduced ejection fraction. Studies have reported improvements in left ventricular ejection fraction following kidney transplantation, with some patients achieving normal function post-transplant. However, guidance for transplant candidacy in patients with heart failure with preserved ejection fraction remains unclear, and management options are limited by drug eligibility and a paucity of specific studies in this population.
One of the most significant concerns raised in the review is the risk of overinclusive cardiovascular assessment leading to delays in transplantation. A retrospective study of 1,573 kidney transplant recipients found that the median time from referral to transplantation was 474 days for those without stress testing, 1,053 days for those requiring stress testing, and 1,687 days for those requiring coronary angiography. Prolonged time on dialysis is a well-recognized predictor of poor post-transplant outcomes. The review argues that excessive testing may result in the loss of transplant candidacy due to the onset of other medical conditions, particularly in cases of preemptive transplantation or living donation where timelines are compressed.
The authors note that current evaluation patterns may not be achieving the goal of making transplantation safer by identifying disease where revascularization would affect prognosis. In a quasi-experimental analysis, low-risk populations did not have worse outcomes after transplantation compared to those without testing. This suggests that routine screening in asymptomatic, low-risk individuals may not provide significant clinical benefit. The review emphasizes the need for large prospective trials to evaluate clinical outcomes associated with pre-transplant cardiovascular evaluation, as current evidence is largely retrospective and observational.
Future directions include the Canadian-Australasian Randomized trial of screening kidney transplant candidates for coronary artery disease (CARSK), which is randomizing asymptomatic patients to routine screening or no further screening while on the waitlist. The results of this trial may help determine the optimal interval for testing waitlisted candidates. Additionally, recent studies have explored the use of machine learning and artificial intelligence algorithms to predict cardiovascular outcomes in kidney transplant recipients. While these models have shown promising predictive capabilities, they have not yet been validated outside of their training cohorts. The review concludes that clinicians must tailor evaluation within the limitations of their local practice environments, balancing the diagnostic value of testing against the well-established cardiovascular benefits of timely kidney transplantation.
Optimized medical therapy in the pre-transplant setting follows a pragmatic framework derived from the ISCHEMIA-CKD protocol, which has been adopted by recent American Heart Association guidelines. This approach includes specific lifestyle modifications, such as smoking cessation, a physical activity goal of at least 150 minutes per week, and dietary restrictions limiting saturated fats to less than 7% of total calories. Medical management targets blood pressure below 130/80 mmHg using beta-blockers, renin-angiotensin system inhibitors, calcium channel blockers, or diuretics. Lipid management aims for low-density lipoprotein cholesterol levels below 70 mg/dL, typically achieved with high-dose statins and the addition of ezetimibe. Glycemic control targets a hemoglobin A1c below 8%, while anti-anginal therapy may include sublingual nitroglycerin, long-acting nitrates, or ranolazine. Single antiplatelet therapy is also a component of this regimen. Although newer agents such as nonsteroidal mineralocorticoid receptor antagonists, sodium-glucose cotransporter-2 inhibitors, and glucagon-like peptide-1 receptor agonists have shown cardiovascular benefits in chronic kidney disease populations, their use in patients with kidney failure remains limited by a lack of specific trial evidence in this group.
The Protection against Incidences of Serious Cardiovascular Events Study, or PISCES, offers a potential new therapeutic avenue for this population. This randomized controlled trial enrolled 1,228 participants undergoing hemodialysis, 35% of whom had known coronary heart disease. Participants were randomized to receive either 4 grams of fish oil daily or a placebo. The intervention group experienced a significant reduction in the primary composite endpoint of cardiovascular death, nonfatal myocardial infarction, peripheral vascular disease leading to amputation, and nonfatal stroke. Event rates were 0.31 per 1,000 patient days in the fish oil group compared to 0.61 in the placebo group, corresponding to a hazard ratio of 0.57 with a 95% confidence interval of 0.47 to 0.70. Despite this reduction in cardiovascular endpoints, the study did not demonstrate a statistically significant reduction in all-cause mortality, with a hazard ratio of 0.89 and a 95% confidence interval of 0.73 to 1.01. Given conflicting results from previous fish oil trials in the general population, the adoption of this strategy may be guided by confirmatory studies, though it suggests a promising option for cardiovascular risk reduction in a population with few treatment alternatives.
Assessment of arrhythmia in potential kidney transplant recipients is guided by limited data, with an electrocardiogram recommended for nearly all patients to rule out significant disease. However, there are no recommendations for more extensive screening in asymptomatic patients with a normal electrocardiogram and no history of arrhythmia. The PRETRANSPLANT study followed a cohort of 100 hemodialysis patients on the kidney transplant list using implantable loop recorders for eight months. The study found that 98% of participants had some form of arrhythmia, primarily supraventricular arrhythmia, ventricular arrhythmia, or nonsustained atrial tachycardia. Most of these findings were not clinically significant, and only five potentially serious arrhythmias were recorded, resulting in just one patient being referred for pacemaker implantation. These findings suggest that routine medium-term monitoring in this population is unlikely to be cost-effective or provide significant clinical benefit.
Pulmonary hypertension affects approximately one-fourth of patients with kidney failure and is often linked to hypertensive heart disease and hypervolemia. In this population, pulmonary hypertension is associated with poor patient and graft survival. Patients with pulmonary artery systolic pressures greater than 35 mmHg had a higher risk of a composite of death, graft failure, or graft dysfunction at five years, with a risk ratio of 1.4 and a 95% confidence interval of 1.2 to 1.7. However, several studies have reported improvements in pulmonary hypertension parameters following kidney transplantation. One study noted that up to 25% of a cohort of 14 patients with pre-transplant pulmonary artery systolic pressures exceeding 60 mmHg recovered post-transplant. Both KDIGO 2020 and the Cardiological Society of India and Indian Society of Nephrology 2025 position statement recommend that patients with severe pulmonary hypertension, defined as pulmonary artery systolic pressures greater than 60 mmHg, be evaluated for transplant candidacy on a case-by-case basis, considering the etiology of the condition and life expectancy.
Subject of Research: Pre-kidney transplant cardiovascular evaluation guidelines and evidence
Article Title: The Pre-Kidney Transplant Cardiovascular Evaluation: A Narrative Review of Current Scientific Statements and Consensus Documents
Article References: Michaud, J. B., Al-Zaneen, G., Anderson, K., Ghimire, A., Tennankore, K. K., Vinson, A. J., & Worthen, G. L. (2026). The Pre-Kidney Transplant Cardiovascular Evaluation: A Narrative Review of Current Scientific Statements and Consensus Documents. Cardiology and Therapy, 15(2), 155-170. https://doi.org/10.1007/s40119-026-00448-6
Image Credits: AI Generated
DOI: 10.1007/s40119-026-00448-6
Keywords: kidney transplant, cardiovascular disease, clinical guidelines, narrative review, hemodialysis, coronary heart disease, medical therapy, revascularization, patient outcomes, clinical practice, Pre-Kidney, Transplant
News Source: Ophelia Keating. (November 10, 2026). Review Questions Routine Heart Screening Before Kidney Transplant. Scienmag.



